{"id":"W3190145293","doi":"10.1016/j.ygyno.2021.07.016","title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Neutropenia; Nausea; Vomiting; Placebo; Oncology; Anemia; Ovarian cancer; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001324257,0.0001672255,0.001141506,0.00009942799,0.00004242747,0.000006980739,0.0000874211,0.0001941986,0.0003065731],"category_scores_gemma":[0.001920189,0.0001066637,0.00007490136,0.0004178554,0.0003979545,0.00008315196,0.00002694115,0.0003235142,9.103993e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004799962,"about_ca_system_score_gemma":0.0007763082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002686596,"about_ca_topic_score_gemma":0.003285401,"domain_scores_codex":[0.9973592,0.0009977306,0.0007471813,0.0004017558,0.0001967908,0.0002974116],"domain_scores_gemma":[0.9961617,0.00290704,0.0003822247,0.0002596581,0.0002344879,0.0000548655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8849953,0.004983613,0.02786956,0.00006456648,0.00009914864,0.0004403538,0.003762201,0.0002434581,0.0004529977,0.0004266592,0.0001678161,0.07649431],"study_design_scores_gemma":[0.9132423,0.003438423,0.08016679,0.00007857393,0.00007712963,0.00001474108,0.0006648155,0.0001931157,0.0002198103,0.00109192,0.0006999547,0.0001123695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904302,0.0003290626,0.0001836038,0.004378939,0.0003507877,0.003362216,0.00002387947,0.00001551616,0.0009258011],"genre_scores_gemma":[0.9943642,0.0003327926,0.00107449,0.002239416,0.00004761852,0.001845631,0.00005557845,0.000009452277,0.00003084629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07638194,"threshold_uncertainty_score":0.4349618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01888383592380004,"score_gpt":0.3414188082779412,"score_spread":0.3225349723541411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}